Soleil Securities initiates coverage on Savient Pharmaceuticals (Nasdaq: SVNT) with a Buy. Price target $21.

Soleil analyst says, "SVNT's Krystexxa ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE